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Abstract
We investigated the clinical efficacy and safety of HESA-A (a drug of herbal-marine origin) in the 
treatment of age related macular degeneration (AMD). In a randomized double blind clinical trial 280 eyes of 280 
(157 F, 123 M) patients with wet and dry AMD were randomly assigned in treatment or placebo groups. Patients in 
treatment group received HESA-A tablet 25 mg/Kg twice a day orally and controls received placebo with the same 
method for 4 weeks. Visual acuity at baseline and after one month of treatment was measured and compared between 
two groups. All patients were followed up for 5 months after treatment. Mean patients’ age was 69.06±8.49 years. At 
the end of study visual acuity improved significantly from 1.69±0.65 LogMar to 1.03± 0.40 LogMar in treatment 
group but not in controls (P: 0.000 and P: 0.67 in treatment and control groups  respectively). No drug reaction or 
recurrence was reported during the study and 5-month post treatment follow up period in HESA-A treated group.
This study showed significant efficacy and safety of HESA-A in improvement of visual acuity in AMD patients in 
short term.
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Introduction
Age-related macular degeneration (AMD) is the most common cause of severe visual loss and blindness in 
people over 50 years of age (Klein et al., 1992; Imrie and Bailey, 2007). The age-adjusted prevalence of AMD is 
about 3.1% which rapidly increases with age (Klein et al., 1992; Mitchell et al., 1995; Vingerling et al.,1995; 
Nirmalan et al., 2004). 
Approximately 50-60% of patients with advanced AMD develop severe visual loss during five years. 
Considering this visual loss, AMD and its following consequences role decrease quality of life in aged patients and
any improvement in visual acuity by treatment could improve quality of life of these patients (Kyo et al., 2007).
However by increasing the life expectancy and proportion of the aged population (doubling of the proportion of 
individuals over 65 years of age by 2030), AMD is becoming a growing socio-medical problem all over the world. 
On the basis of clinical appearance, AMD is classified as dry (non-neovascular) or wet (neovascular). There is no 
specific treatment for dry AMD. Wet AMD stand for only 10% of the overall disease prevalence, but is responsible 
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The main purpose of treatment is to reduce visual loss and its associated physical and emotional impairment 
and to optimize vision related quality of life (Schmidt-Erfurth et al., 2007). During the past years many different
treatments such as phototherapy, photocoagulation, antagonists of vascular endothelial growth factor (VEGF) and 
steroids have been used to manage AMD but they couldn’t achieve desirable results (Giuliari and Ciardella, 2007).
The results of visual outcomes after treatment with these new therapeutic modalities not only are not satisfactory but 
also have been associated with high rates of reactivation and recurrence which needs frequent retreatments
(Blumenkranz, et al., 2002; Gillies, et al., 2003; Gragoudas, et al., 2004; Spaide, 2006).  
HESA-A is a recently developed natural drug in Iran which contains elements such as CaO (43.787%), 
P2O5 (6.63%), Na2O (3.689), MgO (2.897%), SO3 (2.193%), K2O (1.988%), SiO2 (1.09%), Fe2O3 (0.375%), 
Al2O3 (0.354%) as well as Tm, Zn, Cu, Ag, As, Mn, Ti, Sr, Br, Ca, Se, Te, Cd, Cs, Er, Lu and other trace elements 
at very low quantities (Ahmadi et al., 2001a; Ahmadi and Sadeghi-Aliabadi,  2003). The anti-tumor properties of 
some of these elements have been demonstrated (Sadeghi Aliabadi and Ahmadi 2001). HESA-A is currently 
approved for use in humans for cancer treatment and its anticancer effects has been studied in vivo and in vitro
(Sadeghi Aliabadi and Ahmadi, 2001; Ahmadi et al., 2001b; Ahmadi and Sadeghi-Aliabadi, 2003), also 
hepatoprotective effect of HESA-A against hepatic damage was approved in animals in our previous study (Ahmadi 
et al., 2005). Considering the physiological properties of components in HESA-A, the present study was conducted 
to investigate the clinical efficacy and safety of this natural drug in the treatment of AMD. 
Materials and Methods
This randomized double blind clinical trial was conducted on 280 patients (157 F, 123 M) with wet and dry 
AMD. Patients with a clinical diagnosis of dry or wet AMD confirmed by Fluorescein angiography were entered the 
study and randomly assigned to treatment (140 patients) or control group (140 patients). Patients were selected from 
outpatient hospital clinic and private ophthalmology clinics in Tehran and Isfahan between December 2006 and April
2007. The study protocol was approved by Institute of Cancer Research, Medical Sciences/ University of Tehran, 
Shahid Beheshti University of Medical Sciences and Isfahan University of Medical Sciences. The study was 
performed in accordance with the ethical standards of the 1964 Declaration of Helsinki. All patients gave informed 
consent before enrollment to the study. Patients in treatment group received HESA-A tablet 25 mg/Kg twice a day
orally and controls received placebo with the same method for 4 weeks. Patient and physician were blind about the 
drug or placebo group. 
Patients with diagnosis of cataract, glaucoma, corneal lesions and other macular pathologies were excluded 
from the study. All examinations and assessments were performed by a single physician. All patients were followed 
for 6 months after treatment and were reassessed monthly for any drug reaction or disease progress or reactivation. 
Best-corrected visual acuity (BCVA) was measured at baseline and in each visit (monthly) using early treatment 
diabetic retinopathy study (ETDRS) chart. Visual acuity was converted to logMAR score (Minimum Angle of 
Resolution) before analysis. Data analysis was performed using SPSS software version 11.5 for Windows. The data 
were analyzed with descriptive statistics. Paired and independent sample t-test were applied for analysis of continues 
data and P <0.05 was considered to be significant.
Results
In this clinical trial, 280 patients (56.1% female, 43.9% male) with wet and dry AMD were included. Mean 
age of patients was 69.06±8.49 years (49-90 years), which was not different between cases and controls (p>0.05, 
independent t-test). Demographic characteristic of the patients have been shown in table 1. The mean BCVA was not 
different between 2 groups before treatment. At the end of study BCVA improved significantly from 20/400 (1/400-
120/400) to 59/400 (5/400- 280/400) in treatment group but not in controls (P: 0.000 and P: 0.67 in treatment and 
control groups, respectively) (Table 2). Visual acuity improved in all patients in treatment group (100%) following 4 
weeks of treatment and 5 months follow up. The same effect was not observed in control group. 
There was a significant correlation between visual acuity before and after the treatment (r: 0.8. P: 0.000) and patients 
who had better visual acuity before treatment achieved better visual acuity after treatment. No adverse drug reaction 
or drug incompliance was reported during the 4 week treatment and 5 months follow up study. 
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Table 1: Demographic characteristics of patients in case and control group
Variable Case Controls P value
No 140 140 -
Age (years) 69.41± 8.98 68.72± 7.99 0.50
Sex 76 F , 64 M 81 F, 59 M 0.63
                                  P<0.05 significant






Visual acuity at baseline (LogMar) (Mean±SD) 1.69±0.65 1.71±0.65 0.81
Visual acuity after 1 month (LogMar) (Mean±SD) 1.03± 0.40 1.72±0.66 0.000*
P value (before and after) 0.000* 0.67 -
                                 P< 0.05 significant
Discussion
This study showed significant efficacy of HESA-A in improvement of visual acuity in AMD patients 
without any side effect in short term. The recently new options offered for treatment of AMD are antiangiogenic 
drugs, of them anti-VEGFs are the most recent ones and are subjected to investigation. The main disadvantages of 
anti-VEGF therapies (pegaptanib and ranibizumab) are the need for repeated intravitreal injections (with a 0.1% risk 
of endophthalmitis in each injection), high cost and the need for long term (2 or more years) treatment (Korotkin et 
al., 2006).
                             Figure 1: Various stage of fluorescein angiography in age related macular degeneration 
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Although, anti-angiogenic treatments provide vision maintenance in over 90% and considerable
improvement in 25-40% of patients, but yet the recurrence rate is high and visual improvement is not satisfactory
(Ruiz-Moreno et al. 2006). With photodynamic therapy alone for treatment of AMD, the need for retreatment is 
90.8% after 3 months and slightly less after 6 months (Schmidt-Erfurth and Pruente, 2007) which is associated with 
high cost and is time consuming. However with present treatments using either phototherapy or one of the anti-
VEGF drugs, the need for several retreatments and the lack of significant improvement in vision are major concerns.
HESA-A is a recently developed natural drug in Iran with herbal-marine origin. The safety and efficacy of 
this drug in cancer patients has been confirmed previously (Ahmadi et al., 2001a; Ahmadi et al., 2001b; Sadeghi 
Aliabadi and Ahmadi, 2001; Ahmadi and Sadeghi-Aliabadi, 2003; Ahmadi et al., 2005). In the present study after 4 
weeks of treatment with HESA-A there was no need for retreatment in our patients up to 5 months follow up. HESA-
A in comparison to present treatments of AMD seems to be superior due to its efficacy, simple oral usage and short 
treatment course. The exact mechanism of drug action for this natural drug in present study is not known, but its anti-
inflammatory and antioxidant effects which have been confirmed in previous studies (unpublished data). As it is 
recently developed natural drug its pharmacological effect, long term side effect and optimal therapeutic dosage 
should be determined in future studies.
Conclusion
In this study treatment of HESA-A for 4 weeks to AMD patients improved visual acuity. The effect was 
obvious up to 5 months post treatment.
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